Last 46 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Dynavax Technologies Corporation's quarterly P/E stands at 11.8x, down 53.3% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 58.6% YoY to 15.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 77.50 | 11.82 | 17.71 | — | 69.25 | 25.32 | 34.24 | — | 2184.38 | 39.83 | 120.97 | — | 5.91 |
| — | -53.3% | -48.3% | — | -96.8% | -36.4% | -71.7% | — | +36853.7% | +556.2% | +3243.8% | — | -7.6% | |
| P/S Ratio | 6.56 | 3.57 | 3.60 | 5.94 | 6.78 | 5.35 | 5.88 | 7.95 | 8.38 | 8.19 | 6.90 | 6.69 | 2.19 |
| — | -33.2% | -38.8% | -25.3% | -19.1% | -34.7% | -14.8% | +19.0% | +283.0% | +247.4% | +274.8% | +88.2% | -2.9% | |
| P/B Ratio | 3.46 | 2.54 | 2.78 | 3.05 | 3.27 | 2.53 | 2.70 | 2.61 | 3.00 | 3.76 | 2.88 | 2.23 | 2.78 |
| — | +0.2% | +2.9% | +16.8% | +9.3% | -32.8% | -6.3% | +17.4% | +7.8% | +19.1% | -35.5% | -60.5% | -64.9% | |
| P/FCF | 30.24 | 10.39 | 15.61 | — | 9.86 | 23.79 | 43.66 | — | 38.68 | 18.50 | 15.22 | 11.91 | 12.10 |
| — | -56.3% | -64.2% | — | -74.5% | +28.6% | +186.8% | — | +219.7% | +181.9% | -55.7% | — | +223.3% | |
| EV / EBITDA | 503.23 | 15.83 | 23.67 | — | 1203.09 | 38.22 | 58.39 | — | — | 85.19 | — | — | 6.47 |
| — | -58.6% | -59.5% | — | — | -55.1% | — | — | — | +1205.6% | — | — | +35.0% | |
| EV / EBIT | — | 12.42 | 17.25 | — | 51.80 | 21.56 | 28.27 | — | 139.67 | 38.26 | 75.36 | — | 5.99 |
| — | -42.4% | -39.0% | — | -62.9% | -43.7% | -62.5% | — | +2229.7% | +510.8% | +1979.3% | — | +55.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Dynavax Technologies Corporation's operating margin was 22.4% in Q3 2025, up 7.3 pp QoQ and up 9.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 0.2% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.2% | 84.8% | 85.3% | 79.8% | 81.4% | 83.8% | 83.8% | 78.4% | 84.4% | 81.0% | 77.5% | 68.6% | 58.0% |
| — | +1.2% | +1.8% | +1.8% | -3.5% | +3.5% | +8.0% | +14.2% | +45.5% | +27.6% | +14.9% | +5.7% | -6.5% | |
| Operating Margin | -1.5% | 22.4% | 15.1% | -34.7% | -2.3% | 12.5% | 8.2% | -35.0% | -15.3% | 7.4% | -5.7% | -64.5% | 34.2% |
| — | +79.3% | +84.1% | +0.9% | +85.2% | +69.9% | +245.3% | +45.7% | -144.6% | -79.9% | -111.3% | -338.9% | -17.3% | |
| Net Margin | 9.9% | 28.4% | 19.6% | -141.0% | 9.8% | 21.8% | 15.4% | -17.2% | 0.4% | 20.6% | 5.7% | -51.9% | 36.7% |
| — | +30.1% | +27.1% | -721.1% | +2384.7% | +6.1% | +170.9% | +66.9% | -98.9% | -46.0% | -88.7% | -279.9% | -28.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 5.2% | 3.7% | -17.0% | 1.1% | 2.7% | 1.8% | -1.4% | 0.0% | 2.4% | 0.6% | -4.3% | 12.5% |
| — | +97.1% | +102.3% | -1112.1% | +2989.9% | +9.9% | +200.2% | +66.9% | -99.7% | -82.5% | -98.3% | -133.0% | -81.8% | |
| ROA | 2.8% | 2.9% | 2.0% | -9.9% | 0.7% | 1.7% | 1.1% | -0.9% | 0.0% | 1.5% | 0.4% | -2.5% | 6.8% |
| — | +70.6% | +76.6% | -1031.3% | +3000.9% | +13.1% | +215.8% | +64.7% | -99.7% | -76.3% | -97.2% | -177.6% | -33.0% | |
| ROIC | -0.4% | 2.4% | 1.5% | -2.3% | -0.2% | 0.9% | 0.6% | -1.8% | -0.9% | 0.6% | -0.4% | -3.5% | 7.9% |
| — | +151.7% | +151.7% | -28.7% | +82.4% | +62.3% | +246.2% | +48.7% | -111.2% | -93.7% | -101.7% | -131.4% | -92.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Dynavax Technologies Corporation's Debt/EBITDA ratio is 12.2x, down from 17.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 42.4% YoY to 7.62x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.43 | 0.53 | 0.58 | 0.54 | 0.43 | 0.37 | 0.40 | 0.41 | 0.41 | 0.43 | 0.45 | 0.46 | 0.44 |
| — | +45.4% | +45.5% | +30.1% | +3.2% | -13.8% | -11.1% | -9.5% | -7.0% | -17.4% | -26.7% | -49.0% | -61.6% | |
| Debt / EBITDA | 64.74 | 12.20 | 17.34 | — | 579.54 | 20.61 | 31.76 | — | — | 36.86 | — | — | 3.99 |
| — | -40.8% | -45.4% | — | — | -44.1% | — | — | — | +799.1% | — | — | +28.0% | |
| Current Ratio | 10.80 | 7.62 | 6.65 | 11.93 | 10.80 | 13.23 | 14.18 | 15.20 | 13.81 | 15.40 | 17.78 | 9.07 | 6.11 |
| — | -42.4% | -53.1% | -21.5% | -21.8% | -14.1% | -20.2% | +67.6% | +126.1% | +302.9% | +542.3% | +349.6% | +249.6% | |
| Quick Ratio | 9.91 | 6.94 | 6.01 | 10.84 | 9.91 | 12.34 | 13.18 | 14.10 | 12.96 | 14.49 | 16.59 | 8.44 | 5.71 |
| — | -43.8% | -54.4% | -23.1% | -23.6% | -14.9% | -20.6% | +67.0% | +126.7% | +325.9% | +549.8% | +356.8% | +248.9% | |
| Interest Coverage | -0.61 | 15.46 | 8.79 | -13.97 | -0.96 | 5.93 | 3.57 | -10.48 | -5.02 | 3.03 | -2.02 | -17.94 | 37.49 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DVAX stock.
Dynavax Technologies Corporation's current P/E is 77.5x. The average P/E over the last 3 quarters is 32.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Dynavax Technologies Corporation's current operating margin is -1.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Dynavax Technologies Corporation's business trajectory between earnings reports.